Latest news with #RemunerationReport
Yahoo
16-05-2025
- Business
- Yahoo
Prosafe SE: Correction: 2024 Annual Report
Correction: The below announced Press Release did not include attached ESEF file, there are no changes to the numbers or the wording reported in the Annual report, Remuneration report and Transparency act statement for 2024. The ESEF is now included as an attachement. 30 April 2025 - Prosafe SE today published the Annual report, Transparency Act Statement and Remuneration report for 2024. The Annual report includes the 2024 annual accounts, corporate governance report and sustainability report. On 31 January 2025, Prosafe reported preliminary and unaudited results for the fourth quarter and full year 2024. Today's audited accounts include adjustments to EBITDA and net loss compared to the end-January preliminary figures following the sale of the Safe Concordia completed in March 2025. * EBITDA increased by USD 3.4 from USD 23.8 million to USD 27.2 million due to reversal of demobilisation accruals* Impairment increased from nil to USD 8.4 million due to a realised sale price below the net book value after the reporting date* Net loss for the period increased by USD 4.9 million, from USD 41.8 million to 46.7 million The reports are attached and also available on information/annual-reports/ and on Prosafe also published its annual financial statements in European Single Electronic Format (ESEF), which can be found on the website. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to ( For further information, please contact:Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading 2138001LK2Z2HSER4U15-2024-12-31-0-en Prosafe Remuneration report 2024 Prosafe Transparency Act Statement 2024 Prosafe Annual report 2024Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
IDEX Biometrics ASA: Annual General Meeting agenda update
IDEX Biometrics ASA (the 'Company') refers to its stock exchange announcement on 30 April 2025 regarding notice of an annual general meeting scheduled for 21 May 2025 (the 'AGM'). In accordance with Section 6-16b of the Public Limited Liability Companies Act, the Board has prepared a report on the salary and other remuneration of executive management of the Company in 2024 ('Remuneration Report'), and the Company's auditors have issued an assurance report in relation to such Remuneration Report, both of which are available on The Remuneration Report will be subject to an advisory vote by the Company's AGM to be held on 21 May 2025, under a new agenda item 15. Electronic proxy- and voting instruction forms will be updated accordingly. The Board proposes that the AGM approves the following resolution: «The Annual General Meeting approves the remuneration report for 2024.» For the avoidance of doubt, the proposed resolution text is translated to Norwegian: «Generalforsamlingen gir sin tilslutning til rapport om lønn og annen godtgjørelse for ledende personer for regnskapsåret 2024.» For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@ About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit About this notice: This notice was issued by Kristian Flaten, CFO, on 12 May 2025 at 18:00 CET on behalf of IDEX Biometrics ASA. This information is subject to the disclosure requirements pursuant to the Norwegian Securities Trading Act section in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
IDEX Biometrics ASA: Annual General Meeting agenda update
IDEX Biometrics ASA (the 'Company') refers to its stock exchange announcement on 30 April 2025 regarding notice of an annual general meeting scheduled for 21 May 2025 (the 'AGM'). In accordance with Section 6-16b of the Public Limited Liability Companies Act, the Board has prepared a report on the salary and other remuneration of executive management of the Company in 2024 ('Remuneration Report'), and the Company's auditors have issued an assurance report in relation to such Remuneration Report, both of which are available on The Remuneration Report will be subject to an advisory vote by the Company's AGM to be held on 21 May 2025, under a new agenda item 15. Electronic proxy- and voting instruction forms will be updated accordingly. The Board proposes that the AGM approves the following resolution: «The Annual General Meeting approves the remuneration report for 2024.» For the avoidance of doubt, the proposed resolution text is translated to Norwegian: «Generalforsamlingen gir sin tilslutning til rapport om lønn og annen godtgjørelse for ledende personer for regnskapsåret 2024.» For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@ About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit About this notice: This notice was issued by Kristian Flaten, CFO, on 12 May 2025 at 18:00 CET on behalf of IDEX Biometrics ASA. This information is subject to the disclosure requirements pursuant to the Norwegian Securities Trading Act section while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
04-04-2025
- Business
- Yahoo
Aker Solutions ASA: Annual, Remuneration and Corporate Governance reports for 2024
OSLO, Norway, April 4, 2025 /PRNewswire/ -- Aker Solutions today publishes its annual report, remuneration report and corporate governance report for 2024. The reports are attached and also available on and Aker Solutions has also published its annual financial statements in European Single Electronic Format (ESEF), available as an attachment to this release. CONTACT: Preben Ørbeckinvestor 470 10 611 Hallvard Norummedia 913 80 820 This information was brought to you by Cision The following files are available for download: AKSO - Annual report 2024 Remuneration Report 2024 Corporate Governance Report 2024 View original content:
Yahoo
27-03-2025
- Business
- Yahoo
Alligator Bioscience Publishes Annual Report for 2024
LUND, SWEDEN / / March 27, 2025 / Alligator Bioscience (STO:ATORX) today announced that the Annual Report for 2024, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report. The Annual Report and the Remuneration Report are attached as PDFs and are available on the company's website. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 Johan Giléus, CFOE-mail: +46 (0) 46 540 82 00 This information is information that Alligator Bioscience is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-27 19:00 CET. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Annual Report 2024 EN VFAlligator Remuneration Report 2024 EN VF SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
